Key Documents

View All Documentation

Y0001018

Cisplatin impurity A

Name: Cisplatin impurity A
Brand: SIAL

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

trans-Platinum(II)diammine dichloride, trans-Diamminedichloroplatinum(II), trans-Dichlorodiammineplatinum(II)

Select a Size

Change View

About This Item

Linear Formula:

Pt(NH₃)₂Cl₂

CAS Number:

14913-33-8

Molecular Weight:

300.05

NACRES:

NA.24

PubChem Substance ID:

329831221

UNSPSC Code:

41116107

MDL number:

MFCD00011623

Technical Service

Need help? Our team of experienced scientists is here for you.

Let Us Assist

Properties

grade

pharmaceutical primary standard

API family

cisplatin

manufacturer/tradename

EDQM

mp

340 °C (dec.) (lit.)

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

N.N.Cl[Pt]Cl

InChI

1S/2ClH.2H3N.Pt/h2*1H;2*1H3;/q;;;;+2/p-2

InChI key

LXZZYRPGZAFOLE-UHFFFAOYSA-L

Description

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Cisplatin impurity A EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

pictograms

GHS08,GHS05

signalword

Danger

hcodes

H317,H318,H334

pcodes

P280 - P302 + P352 - P305 + P351 + P338 + P310

Hazard Classifications

Eye Dam. 1 - Resp. Sens. 1 - Skin Sens. 1

Storage Class

11 - Combustible Solids

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Epigenetic silencing of microRNA-199b-5p is associated with acquired chemoresistance via activation of JAG1-Notch1 signaling in ovarian cancer.

Michelle X Liu et al.

Oncotarget, 5(4), 944-958 (2014-03-25)

Epithelial ovarian cancer is a highly lethal and aggressive gynecological malignancy. The high mortality rate is due in part to the fact that many advanced cancer patients become refractory to current chemotherapeutic agents, leading to tumor recurrence and death. However

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.

James Chih-Hsin Yang et al.

The Lancet. Oncology, 16(2), 141-151 (2015-01-16)

We aimed to assess the effect of afatinib on overall survival of patients with EGFR mutation-positive lung adenocarcinoma through an analysis of data from two open-label, randomised, phase 3 trials. Previously untreated patients with EGFR mutation-positive stage IIIB or IV

FGFR1 activation is an escape mechanism in human lung cancer cells resistant to afatinib, a pan-EGFR family kinase inhibitor.

Koichi Azuma et al.

Oncotarget, 5(15), 5908-5919 (2014-08-15)

Most NSCLC patients with EGFR mutations benefit from treatment with EGFR-TKIs, but the clinical efficacy of EGFR-TKIs is limited by the appearance of drug resistance. Multiple kinase inhibitors of EGFR family proteins such as afatinib have been newly developed to

View All Related Papers

Global Trade Item Number

SKU	GTIN
Y0001018	04061837583971